StockData
Akari Therapeutics Plc logo

Akari Therapeutics Plc (AKTX) stock

AKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 0/30
$6.65+0.95 (+16.67%)

Close on Nov 18, 2026Market cap $12.95MP/E –Yield –

Akari Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Akari Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$10.76M. For fiscal 2025 it was -$10.57M. The highest annual figure on record is -$366.00K in fiscal 2010.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$10.57M–
FY2024Dec 31, 2024-$12.55M–
FY2023Dec 31, 2023-$16.43M–
FY2022Dec 31, 2022-$21.50M–
FY2021Dec 31, 2021-$18.85M–
FY2020Dec 31, 2020-$16.95M–
FY2019Dec 31, 2019-$12.92M–
FY2018Dec 31, 2018-$22.77M–
FY2017Dec 31, 2017-$31.60M–
FY2016Dec 31, 2016-$24.62M–
FY2015Dec 31, 2015-$4.97M–
FY2014Dec 31, 2014-$1.48M–
FY2013Dec 31, 2013-$5.45M–
FY2012Dec 31, 2012-$2.13M–
FY2011Dec 31, 2011-$1.01M–
FY2010Dec 31, 2010-$366.00K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.11M–
Q1 FY2026Mar 31, 2026-$2.49M–
Q4 FY2025Dec 31, 2025-$3.04M–
Q3 FY2025Sep 30, 2025-$2.12M–
Q2 FY2025Jun 30, 2025-$3.26M–
Q1 FY2025Mar 31, 2025-$2.15M–
Q4 FY2024Dec 31, 2024-$2.12M–
Q3 FY2024Sep 30, 2024-$1.49M–
Q2 FY2024Jun 30, 2024-$4.89M–
Q1 FY2024Mar 31, 2024-$4.04M–
Q4 FY2023Dec 31, 2023-$4.41M–
Q3 FY2023Sep 30, 2023-$2.45M–
Q2 FY2023Jun 30, 2023-$4.69M–
Q1 FY2023Mar 31, 2023-$4.88M–
Q4 FY2020Dec 31, 2020-$4.23M–
Q3 FY2020Sep 30, 2020-$704.17K–
Q2 FY2020Jun 30, 2020-$4.27M–
Q1 FY2020Mar 31, 2020-$7.74M-3480.6%
Q4 FY2019Dec 31, 2019-$3.46M–
Q3 FY2019Sep 30, 2019-$4.91M–
Q2 FY2019Jun 30, 2019-$4.77M–
Q1 FY2019Mar 31, 2019$228.94K-94.9%
Q2 FY2016Jun 30, 2016-$5.69M–
Q1 FY2016Mar 31, 2016-$7.44M–
Q4 FY2015Dec 31, 2015-$6.77M–
Q3 FY2015Sep 30, 2015$4.49M+25.9%
Q2 FY2015Jun 30, 2015-$697.54K–
Q1 FY2015Mar 31, 2015-$1.99M–
Q4 FY2014Dec 31, 2014-$667.98K–
Q3 FY2014Sep 30, 2014$3.57M–
Q2 FY2014Jun 30, 2014-$2.33M–

More Akari Therapeutics figures

See a number that looks wrong?